Advocacy intelligence hub — real-time data for patient organizations
Gruppo Italiano Malattie EMatologiche dell'Adulto
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Mylotarg
(Gemtuzumab ozogamicin)Orphan drugstandardWyeth Pharmaceuticals, Inc., a Pfizer Company
CD33-directed Immunoconjugate [EPC]
12.1 Mechanism of Action Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate (ADC). The antibody portion (hP67.6) recognizes human CD33 a...
B. Smith, M.S.W., L.C.S.W
Johns Hopkins University
📍 OKLAHOMA CITY, OK
Soheil Meshinchi, MD, MD,PhD
Fred Hutchinson Cancer Center
📍 SEATTLE, WA
Bart Scott
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Guido Marcucci, M.D
Ohio State University
📍 DUARTE, CA
Thomas G. Martin, MD
University of California, San Francisco
Colleen Delaney, MD
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 OLD GREENWICH, CT